Phase I Study of Inhaled Doxorubicin in Patients With Advanced Solid TumorsAffecting the Lungs
(Summary Last Modified 04/2002)
PATIENT ABSTRACT
RATIONALE:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE:
Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tumors affecting the lungs.
ELIGIBILITY:
At least 18 years old
Measurable or evaluable disease
At least 4 weeks since biological therapy, chemotherapy, or radiation therapy
No previous trastuzumab
At least 1 year since radiation therapy to the chest
No previous surgery to remove the lung
TREATMENT:
Patients will inhale doxorubicin every 3 weeks for up to three doses. Some patients will continue treatment for as long as benefit is shown. Patients will be evaluated at 3 weeks and 3 months.
This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial eligibility and the treatment plan, please see the Health Professional abstract of this clinical trial. For more information about clinical trials, please visit the NCI cancerTrials website at http://cancertrials.nci.nih.gov
PROTOCOL IDS
NCI-00-C-0088
PARTICIPATING ORGANIZATIONS/STUDY CONTACTS
David S. Schrump, Chair Ph: 301-496-2127
Center for Cancer Research
STUDY CONTACTS
Maryland
Patient Recruitment, Ph: 1-888-NCI-1937
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, U.S.A.
** POSTED APRIL 30, 2002 **